United Therapeutics (UTHR)
(Real Time Quote from BATS)
$339.42 USD
-1.69 (-0.50%)
Updated Sep 13, 2024 01:08 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 541 - 560 ( 609 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Corporate Update: We Believe the Company Can Address Three Key Issues Causing Overhang on the Stock
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
ATS Preview: Data Presentations Support Clinical Profiles For Adcirca, Tyvaso, Remodulin, Oral Treprostinil and Beraprost
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1:12 Revenues and Earnings Beat, 2012 Revenue Guidance Reconfirmed, Reiterate UTPERFORM and $91 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Believe Consensus for Product Sales Is Achievable
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FDA Acceptance Of Oral Treprostinil NDA Solidifies The Timing For Potential Approval In Q
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
4Q11 Results Review: Revenue Comes in Light; Reiterates Prior 2012 & 2013 Guidance
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4:11 Sales Choppy But FY GAAP EPS Beat. Reiterate OUTPERFORM and $91 FV as Growth Remains Intact, in our View.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Consensus for Product Sales Is Achievable. Reiterate OUTPERFORM and $91 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
In Our View The Paragraph IV Certification For Remodulin Is Not A Near-Term Threat To Revenue Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
IV Remodulin Approved in EU and Oral Remodulin NDA Submitted to FDA. Reiterate OUTPERFORM and Raising Fair Value to $91 from $87.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L